From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

GPRC5D-Targeted CAR T Cells for Myeloma

Last Updated: Tuesday, December 27, 2022

Although disease relapse is common for patients with advanced myeloma who have received B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies, the authors of this study confirmed that G protein-coupled receptor, class C, group 5, member D (CPRC5D) in an active immunotherapeutic target in multiple myeloma based on therapeutic response seen in 71% of the 17 patients included.

New England Journal of Medicine
Advertisement
News & Literature Highlights
Advertisement
Advertisement